What Has Changed (again) in HER2 Testing of Breast Cancers


Since HER2 directed therapies became available for treatment of breast cancer, determining HER2 status of breast cancers has been an area of challenge and controversy. Changes in guidelines of HER2 testing and interpretation have contributed to the uncertainty in defining what is HER2 positive. This lecture will review briefly the history of HER2 testing and the most recent clinical evidence leading to the 2018 ASCO/CAP update of HER2 testing in breast cancer.

Originally presented on February 13, 2019 in Park City, Utah.

Lecture Presenter

Evin Gulbahce, MD

Evin Gulbahce, MD

Professor of Pathology
University of Utah School of Medicine
Medical Director, Surgical Pathology and Oncology
ARUP Laboratories

Dr. Gulbahce is a professor of pathology at the University of Utah School of Medicine. She received her MD from Hacettepe University in Ankara, Turkey, and completed a residency in anatomic and clinical pathology and a surgical pathology fellowship at the University of Minnesota. Her research interests include pulmonary complications of solid organs, hematopoietic stem cell transplantation, and breast cancer risk factors, specifically risk factor for basal-like and triple negative cancers.


After this presentation, participants will be able to:

  • Identify the pre-analytical and analytical factors that may contribute to erroneous reporting of HER2 in breast cancer
  • Identify the HER2 FISH groups whose interpretation have changed with the 2018 ASCO/CAP update.
  • Apply the recommended testing algorithms for the HER2 FISH Groups 2, 3 and 4

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories